Genetics News

SAN DIEGO--(BUSINESS WIRE)--Element Biosciences, Inc. today announced an upsized Series E round of financing, including $175 million from longstanding investor Samsung Electronics, and an undisclosed amount from other investors. The funding will accelerate commercialization of Element’s growing ecosystem of genomic and multiomic solutions, expand its global presence, and advance its product roadmap across research, translational science, and diagnostic applications. This new capital will suppor...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Cellares, the first Integrated Development and Manufacturing Organization (IDMO), today announced that ARK Invest has joined the company's Series D financing with a $20 million investment, bringing the total Series D to $277 million. ARK joins a high-caliber group of Cellares investors, including BlackRock, Eclipse, T. Rowe Price Investment Management, Inc., Baillie Gifford, Duquesne Family Office, Intuitive Ventures, EDBI, Gates Frontier, DC Global...

SAN FRANCISCO--(BUSINESS WIRE)--Mission Bio, the leader in single-cell multiomics solutions, today announced a collaboration with the Human Cell Atlas (HCA), a global consortium working to create comprehensive reference maps of all human cells to advance the understanding, diagnosis, and treatment of disease. The announcement comes ahead of the upcoming Human Cell Atlas General Meeting 2026, taking place June 16–18 in Boston, where Mission Bio will participate alongside leading researchers and...

BERKELEY, Calif.--(BUSINESS WIRE)--AI can predict a protein’s 3D shape and help design molecules that fit it. Tools like OpenFold make drug discovery faster, cheaper, and more precise....

BOULDER, Colo.--(BUSINESS WIRE)--Watchmaker Genomics, a leader in high-performance NGS workflow solutions, today announced it will unveil two new technologies at the European Society of Human Genetics (ESHG) 2026 conference, designed to address persistent bottlenecks in sequencing workflow scalability and amplification accuracy. The launches include the EquiPlex™ Normalization Kit, which simplifies library normalization using a novel Cas9-based approach, and Equinox® Prime Library Amplification...

SAN MATEO, Calif. & DALLAS--(BUSINESS WIRE)--Curve Biosciences Unveils Scientific Advisory Board Guiding the Advancement of Whole-Body Intelligence for Chronic Disease...

MADISON, Wis.--(BUSINESS WIRE)--Promega receives SBTi validation for near-term science-based emissions reduction targets covering Scope 1, 2 and 3 through 2030....

FREMONT, Calif.--(BUSINESS WIRE)--Personalis, Inc. (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, today announced that its Personalis EDTA Blood Collection Kit and Personalis cfDNA Blood Collection Kit have obtained Class A CE-IVD marking in compliance with the European Union’s In Vitro Diagnostic Regulation (IVDR). The CE Mark represents an important regulatory milestone, ensuring that clinical trial sites throughout the European Union and Great Britain can use these col...

ALISO VIEJO, Calif.--(BUSINESS WIRE)--Ambry Genetics, a leader in clinical genomic testing, and a wholly owned subsidiary of Tempus AI, Inc. (NASDAQ: TEM), announced peer-reviewed research demonstrating the potential for variant-specific RNA testing to provide greater clarity for patients who receive a variant of uncertain significance (VUS) result from exome testing. The study, published in Genetics in Medicine Open, showcases how targeted RNA analysis using Ambry’s ExomeReveal workflow; an in...

FOSTER CITY, Calif., & RAHWAY, N.J.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the primary efficacy endpoint at Week 48 was met in both the Phase 3 ISLEND-1 and ISLEND-2 trials with the investigational oral once-weekly single-tablet HIV treatment regimen of islatravir/lenacapavir. The ISLEND trials are evaluating the efficacy and safety of islatravir 2 mg/lenacapavir 300 mg (ISL/LEN) in...